MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts
TH-302 is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. It is currently being evaluated in clinical trials, including two trials in Pancreatic Ductal Adenocarcinomas (PDAC). The current study was undertaken to evaluate imaging...
| Main Authors: | , , , , , , |
|---|---|
| Other Authors: | |
| Language: | en |
| Published: |
Public Library of Science
2016
|
| Online Access: | http://hdl.handle.net/10150/616994 http://arizona.openrepository.com/arizona/handle/10150/616994 |